Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE - ARGOS THERAPEUTICS INC | newsrelease.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 30, 2015
Argos Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35443 | 56-2110007 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 4233 Technology Drive, Durham, North Carolina | 27704 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (919) 287-6300
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On March 30, 2015, Argos Therapeutics, Inc. (the "Company") announced financial results for the three months and twelve months ended December 31, 2014. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act" or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
99.1
Press Release dated March 30, 2015 entitled "Argos Therapeutics Reports Fourth Quarter 2014 and Year-End Financial Results"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Argos Therapeutics, Inc.
(Registrant) |
||
| March 30, 2015
(Date) |
/s/ JEFFREY D. ABBEY
Jeffrey D. Abbey President and Chief Executive Officer |